Condition: Non Small Cell Lung Cancer · Sponsor: Innate Pharma
In Cohort 1, the study was intended to assess safety and efficacy of neoadjuvant combination of IPH5201 and durvalumab in addition to standard chemotherapy and adjuvant combination of IPH5201 and durvalumab, in untreated patients with resectable, early-stage (stage II to IIIA) non-small cell lung cancer (NSCLC). Study Design was updated following the results of interim analysis # 2 (protocol amendment, adding cohort 2). Cohort 2 includes patients with resectable Stage II to IIIB NSCLC expressing PD-L1 ≥1%, receiving (only) neoadjuvant IPH5201+ durvalumab + chemotherapy
This description comes directly from the study's public registry record.
Innate Pharma · +33484903084 · clinical.trials@innate-pharma.fr
Always discuss trial participation with your own doctor first.
| St. Anthony's Hospital - BayCare Health System | St. Petersburg, Florida, United States | Terminated |
| H. Lee Moffitt Cancer Center & Research Institute | Tampa, Florida, United States | Terminated |
| University of Chicago Medical Center | Chicago, Illinois, United States | Withdrawn |
| Northwell Health Cancer Institute / Center for Novel Cancer Therapeutics | Lake Success, New York, United States | Withdrawn |
| Millennium Research & Clinical Development | Houston, Texas, United States | Terminated |
| UW Carbone Cancer Center - Cancer Connect | Madison, Wisconsin, United States | Terminated |
| Angers University Hospital Center | Angers, France | Terminated |
| University Hospital Center Caen | Caen, France | Terminated |
| Hospital Calmette | Lille, France | Not Yet Recruiting |
| CHU de Limoges | Limoges, France | Recruiting |
| Leon Berard Center | Lyon, France | Recruiting |
| Marseille University Hospital Center - North Hospital | Marseille, France | Recruiting |
+ 18 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05742607